---
document_datetime: 2023-09-21 19:17:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/sprimeo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: sprimeo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3853955
conversion_datetime: 2025-12-25 05:46:36.276257
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Novartis Europharm Ltd. submitted on 5 September 2006 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Sprimeo,  through  the  centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 23 February 2006.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 27 April 2007.

The application submitted is a complete dossier: composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies) Scientific Advice: The  applicant  received  Scientific  Advice  from  the  CHMP  on  3  June  2004.  The  Scientific  Advice pertained to non-clinical and clinical aspects of the dossier. Licensing status: A new application was filed in the following countries: USA, Canada. The product was not licensed in any country at the time of submission of the application. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Giuseppe Nisticó Co-Rapporteur: János Borvendég CHMP Peer reviewers: Alar Irs, Karl Broich 2. Steps taken for the assessment of the product · The application was received by the EMEA on 5 September 2006. · The procedure started on 27 September 2006. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 11 December 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 8 December 2006. · During  the  meeting  on  22-24  January  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 25 January 2007. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 15 March 2007. Medicinal product no longer authorised

- During  the  CHMP  meeting  on  21-24  May  2007,  the  CHMP  agreed  on  a  list  of  outstanding issues to be addressed in writing by the applicant.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding Issues to all CHMP members on 9 June 2007.
- During the meeting on 18-21 June 2007, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Sprimeo  on  21  June  2007.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 15 June 2007.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 22 August 2007.